Ten-Year Incidence of Fatal and Non-Fatal Myocardial Infarction in the Elderly Population of Madrid

Novella, Blanca; Alonso, Margarita; Rodríguez-Salvanés, Francisco; García, Rosario Susi; Reviriego, Blanca; Escalante, Luisa Fernanda Salazar; Suárez, Carmen; Gabriel, Rafael

doi:10.1016/s1885-5857(09)60028-1

Cited by 8 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our global AMI incidence rate is within the range of 132-710 AMI episodes per 100,000 reported by other Spanish studies. 10,[17][18][19][20] There are several possible explanations for the large differences observed in distinct studies, including differences in the study design, study populations, study periods, geographical variations and inclusion criteria of cases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and mortality of myocardial infarction among Catalonian older adults with and without underlying risk conditions: The CAPAMIS study

Forcadell

Vila-Córcoles

Diego

et al. 2018

Eur J Prev Cardiolog

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…The mortality observed in our study is within the range reported in other studies in Spain. 12,17,18,27,33,34 We note that mortality remains considerable despite measures aimed to reduce lethality and sequelae from AMI implemented during the past decade (e.g. the 'AMI code', a national Table 3.…”

Section: Discussionmentioning

confidence: 99%

Incidence and mortality of myocardial infarction among Catalonian older adults with and without underlying risk conditions: The CAPAMIS study

Forcadell

Vila-Córcoles

Diego

et al. 2018

Eur J Prev Cardiolog

View full text Add to dashboard Cite

show abstract

“…The EPICARDIAN is a multicenter, population-based, cohort study in people 65 years and older from three geographical areas of Spain: Madrid city, Arévalo county (Ávila province) and Begonte county (Lugo province). Study design and methods have been previously published elsewhere [13,14]. In summary a total of 3,729 individuals older than 64 years participated in the baseline examination.…”

Section: Methodsmentioning

confidence: 99%

Total Cardiovascular Risk in the Elderly Population of Spain: The Epicardian Risk Score

Gabriel

Muñiz

Vega

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Cardiovascular risk estimation in people over 70 years is problematic. Most scores have been derived from cohorts of middle-aged people, with older persons under-represented. The predictive power of classical cardiovascular risk factors reduce with age. The aim is to develop a specific score for the elderly populationMethods: Population-based cohort established in 1995. Setting: Three geographical areas of Spain (Madrid, Ávila and Lugo). Participants: 3,729 people older than 64 years, free of any cardiovascular diseases (CVD), at baseline. Measurements: Suspected fatal and nonfatal CVD (both coronary heart disease and stroke) were yearly investigated and confirmed using the WHO-MONICA criteria. All participants were followed until the occurrence of the first CVD event, until death or until December 31th 2015 if alive.Results: Age was the strongest predictor of 10-year CVD both in men and women. In men, variables associated to CVD were high blood pressure treatment (HR: 1,35; 95% CI: 1,067 , 1,710), diabetes (HR: 1,359; 95% CI: 0,997 , 1,852) and smoking (HR:1,207; 95%CI: 0,945 , 1,541), and in women smoking (HR: 1,881 95%CI: 1,356 , 2,609) and diabetes (HR:1,285; 95%CI:0,967 , 1,707). Total-cholesterol did not increased the risk of CVD either in males or females. However, total-cholesterol level (>200mg/dl) were negatively associated both in men and women.Conclusions: In old Spanish men, 10-year total CVD is significantly increased by age, diabetes and antihypertensive treatment, and in old women by diabetes and smoking. Total-cholesterol levels did not increased the risk of CVD either in males or females.

show abstract

“…Incidences of AMI and stroke are estimated in 8 and 12 cases per 1000, respectively, in Spanish population [36,37]. Thus, considering a pneumococcal vaccine coverage of approximately 50%,[31] with a p = 0.05 (two-tailed) the size of the study cohort (N = 27,000 individuals followed during a 30-month period) has an statistical power of 80% to detect a posible vaccination effectiveness of 20% against CAP, a 23% against AMI, a 18% against stroke and a 14% against the combined end-point AMI/stroke.…”

Section: Methods and Designmentioning

confidence: 99%

Rationale and design of the CAPAMIS study: Effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke

et al. 2010

View full text Add to dashboard Cite

BackgroundThe 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-risk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute vascular events among patients with pneumonia, and a recent case-control study has reported a reduction in the risk of myocardial infarction among patients vaccinated with PPV-23. Given that animal experiments have shown that pneumococcal vaccination reduces the extent of atherosclerotic lesions, it has been hypothesized that PPV-23 could protect against acute vascular events by an indirect effect preventing pneumonia or by a direct effect on oxidized low-density lipoproteins. The main objective of this study is to evaluate the clinical effectiveness of PPV-23 in reducing the risk of pneumonia and acute vascular events (related or nonrelated with prior pneumonia) in the general population over 60 years.Methods/DesignCohort study including 27,000 individuals 60 years or older assigned to nine Primary Care Centers in the region of Tarragona, Spain. According to the reception of PPV-23 before the start of the study, the study population will be divided into vaccinated and nonvaccinated groups, which will be followed during a consecutive 30-month period. Primary Care and Hospitals discharge databases will initially be used to identify study events (community-acquired pneumonia, hospitalisation for acute myocardial infarction and stroke), but all cases will be further validated by checking clinical records. Multivariable Cox regression analyses estimating hazard ratios (adjusted for age, sex and comorbidities) will be used to estimate vaccine effectiveness.DiscussionThe results of the study will contribute to clarify the controversial effect of the PPV-23 in preventing community-acquired pneumonia and they will be critical in determining the posible role of pneumococcal vaccination in cardiovascular prevention.

show abstract

Ten-Year Incidence of Fatal and Non-Fatal Myocardial Infarction in the Elderly Population of Madrid

Cited by 8 publications

References 32 publications

Incidence and mortality of myocardial infarction among Catalonian older adults with and without underlying risk conditions: The CAPAMIS study

Incidence and mortality of myocardial infarction among Catalonian older adults with and without underlying risk conditions: The CAPAMIS study

Total Cardiovascular Risk in the Elderly Population of Spain: The Epicardian Risk Score

Rationale and design of the CAPAMIS study: Effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke

Contact Info

Product

Resources

About